FEATURED COMPANIES
- 4D Pharma Plc
- Cox Biosciences LLC
- Epigen Biosciences Inc
- Finch Therapeutics
- Insys Therapeutics Inc
- Neurochlore
The 2020 Autism spectrum disorders (ASD) pipeline report presents a comprehensive overview of the research and development of Autism spectrum disorders (ASD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, 13 drugs in Pre-clinical phase, four drugs in Phase 1, seven drugs in Phase 2, four drugs in Phase 3 and one drug in pre-registration.
As of February 2020, the Autism spectrum disorders (ASD) pipeline remains robust with 33 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Autism spectrum disorders (ASD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT2A receptor antagonist; AMPA receptor agonists; Cannabinoid receptor modulators; Dopamine D2 /D3/D4 receptor partial agonists; Dopaminergic cell replacements; Fatty acid amide hydrolase inhibitors; GABA A alpha 5 receptor modulators; histamine agonist; lipopolysaccharides (LPS) antagonist; Melatonin receptor agonists; Metabotropic glutamate receptor 5 modulators; NAV1.2 voltage-gated sodium channel expression stimulants; NF E2 related factor 2 stimulants; opioid receptor antagonist; oxytocin receptor agonist; P70 S6 kinase inhibitor; Serotonin 1A/2A receptor partial agonists; Sodium-potassium-chloride symporter inhibitors; Telomeric 22q13 Monosomy Syndrome; Tyrosine hydroxylase inhibitors; Vasopressin 1 receptor antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Autism spectrum disorders (ASD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Autism spectrum disorders (ASD) pipeline companies included in the report are: 4D Pharma Plc, AgeneBio Inc, BioHealthonomics Inc, Blackthorn Therapeutics Inc, BrainStorm Cell Therapeutics Inc, Cennerv Pharma (S) Pte Ltd, Cox Biosciences LLC, Curemark LLC, Cytocom Inc, Epigen Biosciences Inc, Evgen Pharma Plc, F. Hoffmann-La Roche Ltd, Finch Therapeutics, GW Pharmaceuticals Plc, Immuron Ltd, Insys Therapeutics Inc, Intra-Cellular Therapies Inc, Johnson & Johnson, Neuren Pharmaceuticals, Neurim Pharmaceuticals Ltd, Neurochlore, OptiNose US Inc, Ovensa Inc, RespireRx Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, RogCon Inc, Sengenics, Sosei Heptares, Sumitomo Dainippon Pharma Co Ltd, Translational Biosciences, Yamo Pharmaceuticals LLC, Zelda Therapeutics Pty Ltd.
Autism spectrum disorders (ASD) pipeline drugs profiled in the report include: Biologics for Autism , GABA A alpha 5 receptor modulators for Autistic disorder, histamine dihydrochloride, BTRX-323511, NurOwn, CB0306, levoleucovorin, CM-AT, IRT-103 (naltrexone), EPGN1370, SFX-01, balovaptan, RG-7816, FIN-211, GWP42006 (CBDV), IMM-124E, cannabidiol , ITI-007 (lumateperon), JNJ-5279, Melatonin, bumetanide, OPN-300 (oxytocin), Small Molecule for Autism, CX717, brilaroxazine, RCUR-313, RCUR-SMP, Antibodies for Autism , GPCR modulators(HTL0022562), SM-13496 (lurasidone), Stem Cell Therapy for CNS Disorders, Autism, L1-79, NNZ-2591, ZELDA.
As of February 2020, the Autism spectrum disorders (ASD) pipeline remains robust with 33 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Autism spectrum disorders (ASD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT2A receptor antagonist; AMPA receptor agonists; Cannabinoid receptor modulators; Dopamine D2 /D3/D4 receptor partial agonists; Dopaminergic cell replacements; Fatty acid amide hydrolase inhibitors; GABA A alpha 5 receptor modulators; histamine agonist; lipopolysaccharides (LPS) antagonist; Melatonin receptor agonists; Metabotropic glutamate receptor 5 modulators; NAV1.2 voltage-gated sodium channel expression stimulants; NF E2 related factor 2 stimulants; opioid receptor antagonist; oxytocin receptor agonist; P70 S6 kinase inhibitor; Serotonin 1A/2A receptor partial agonists; Sodium-potassium-chloride symporter inhibitors; Telomeric 22q13 Monosomy Syndrome; Tyrosine hydroxylase inhibitors; Vasopressin 1 receptor antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Autism spectrum disorders (ASD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Autism spectrum disorders (ASD) development
- Autism spectrum disorders (ASD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Autism spectrum disorders (ASD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Autism spectrum disorders (ASD) pipeline candidates included
- Business overview and snapshot of all companies involved in Autism spectrum disorders (ASD) pipeline are included
- Latest market and pipeline developments are provided in the report
Autism spectrum disorders (ASD) pipeline companies included in the report are: 4D Pharma Plc, AgeneBio Inc, BioHealthonomics Inc, Blackthorn Therapeutics Inc, BrainStorm Cell Therapeutics Inc, Cennerv Pharma (S) Pte Ltd, Cox Biosciences LLC, Curemark LLC, Cytocom Inc, Epigen Biosciences Inc, Evgen Pharma Plc, F. Hoffmann-La Roche Ltd, Finch Therapeutics, GW Pharmaceuticals Plc, Immuron Ltd, Insys Therapeutics Inc, Intra-Cellular Therapies Inc, Johnson & Johnson, Neuren Pharmaceuticals, Neurim Pharmaceuticals Ltd, Neurochlore, OptiNose US Inc, Ovensa Inc, RespireRx Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, RogCon Inc, Sengenics, Sosei Heptares, Sumitomo Dainippon Pharma Co Ltd, Translational Biosciences, Yamo Pharmaceuticals LLC, Zelda Therapeutics Pty Ltd.
Autism spectrum disorders (ASD) pipeline drugs profiled in the report include: Biologics for Autism , GABA A alpha 5 receptor modulators for Autistic disorder, histamine dihydrochloride, BTRX-323511, NurOwn, CB0306, levoleucovorin, CM-AT, IRT-103 (naltrexone), EPGN1370, SFX-01, balovaptan, RG-7816, FIN-211, GWP42006 (CBDV), IMM-124E, cannabidiol , ITI-007 (lumateperon), JNJ-5279, Melatonin, bumetanide, OPN-300 (oxytocin), Small Molecule for Autism, CX717, brilaroxazine, RCUR-313, RCUR-SMP, Antibodies for Autism , GPCR modulators(HTL0022562), SM-13496 (lurasidone), Stem Cell Therapy for CNS Disorders, Autism, L1-79, NNZ-2591, ZELDA.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- 4D Pharma Plc
- Cox Biosciences LLC
- Epigen Biosciences Inc
- Finch Therapeutics
- Insys Therapeutics Inc
- Neurochlore
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Note: Product cover images may vary from those shown
- 4D Pharma Plc
- AgeneBio Inc
- BioHealthonomics Inc
- Blackthorn Therapeutics Inc
- BrainStorm Cell Therapeutics Inc
- Cennerv Pharma (S) Pte Ltd
- Cox Biosciences LLC
- Curemark LLC
- Cytocom Inc
- Epigen Biosciences Inc
- Evgen Pharma Plc
- F. Hoffmann-La Roche Ltd
- Finch Therapeutics
- GW Pharmaceuticals Plc
- Immuron Ltd
- Insys Therapeutics Inc
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- Neuren Pharmaceuticals
- Neurim Pharmaceuticals Ltd
- Neurochlore
- OptiNose US Inc
- Ovensa Inc
- RespireRx Pharmaceuticals Inc
- Reviva Pharmaceuticals Inc
- RogCon Inc
- Sengenics
- Sosei Heptares
- Sumitomo Dainippon Pharma Co Ltd
- Translational Biosciences
- Yamo Pharmaceuticals LLC
- Zelda Therapeutics Pty Ltd
Note: Product cover images may vary from those shown